{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:06:41Z","timestamp":1787317601515,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,10,31]],"date-time":"2007-10-31T00:00:00Z","timestamp":1193788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:p>\n                    <jats:list list-type=\"explicit-label\">\n                      <jats:list-item>\n                        <jats:p>The aim of the present study was to investigate the effect and mechanism of berberine, an alkaloid extracted from the traditional Chinese medicine coptis, on rat liver fibrosis induced by multiple hepatotoxic factors.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          Male Wistar rats were separated into five groups, a normal control group, a fibrotic control group and fibrotic groups treated with three different doses of berberine. The fibrotic models were established by introduction of multiple hepatotoxic factors, including CCl\n                          <jats:sub>4<\/jats:sub>\n                          , ethanol and high cholesterol. Rats in the treatment groups were administered 50, 100 or 200\u00a0mg\/kg berberine, intragastrically, daily for 4 weeks. Serum levels of alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST), hepatic activity of superoxide dismutase (SOD) and hepatic malondialdehyde (MDA) and hepatic hydroxyproline (Hyp) content were determined. Liver biopsies were obtained for histological and immunohistochemical studies to detect the expressions of a\u2010smooth muscle actin (SMA) and transforming growth factor (TGF)\u2010b1.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          The results showed that, compared with the fibrotic control group, serum levels of ALT and AST and hepatic content of MDA and Hyp were markedly decreased, but the activity of hepatic SOD was significantly increased in berberine\u2010treated groups in a dose\u2010dependent manner. In addition, histopathological changes, such as steatosis, necrosis and myofibroblast proliferation, were reduced and the expression of a\u2010SMA and TGF\u2010b1 was significantly downregulated in the berberine\u2010treated groups (\n                          <jats:italic>P<\/jats:italic>\n                          \u00a0&lt;\u00a00.01).\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>These results suggest that berberine could be used to prevent experimental liver fibrosis through regulation of the anti\u2010oxidant system and lipid peroxidation.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>","DOI":"10.1111\/j.1440-1681.2007.04819.x","type":"journal-article","created":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T01:14:15Z","timestamp":1193879655000},"page":"303-309","source":"Crossref","is-referenced-by-count":69,"title":["PROTECTION BY AND ANTI\u2010OXIDANT MECHANISM OF BERBERINE AGAINST RAT LIVER FIBROSIS INDUCED BY MULTIPLE HEPATOTOXIC FACTORS"],"prefix":"10.1111","volume":"35","author":[{"given":"Ben\u2010Jian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao\u2010bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00429-4"},{"key":"e_1_2_6_3_2","first-page":"1907","article-title":"Drug therapy in chronic liver disease","volume":"94","author":"Maier KP","year":"2005","journal-title":"Schweiz. Rundsch. Med. Prax"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80185-0"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25349"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2741\/A812"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.4811"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.6126"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.09.069"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24282"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.4.2247"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.45.120403.095906"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.5.585"},{"key":"e_1_2_6_14_2","first-page":"425","article-title":"4\u2010Hydroxy\u20102,3\u2010alkenals as molecular mediators of oxidative stress in the pathogenesis of liver fibrosis","volume":"4","author":"Parola M","year":"1999","journal-title":"Int. J. Mol. Med"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1999.tb04206.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007215"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270313"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1995.tb01798.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.48.33881"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.2000.279.6.L1005"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-26761"},{"key":"e_1_2_6_22_2","first-page":"26","article-title":"Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol\u2010lowering agents. A single\u2010blind clinical investigation","volume":"57","author":"Cicero AF","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/jmf.2005.8.454"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2006.71"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2006.04.019"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2005.11.010"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2007.06.004"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-002-0351-9"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1016-8478(23)13249-3","article-title":"Berberine inhibits the production of lysophosphatidylcholine\u2010induced reactive oxygen species and the ERK1\/2 pathway in vascular smooth muscle cells","volume":"20","author":"Cho BJ","year":"2005","journal-title":"Mol. Cell"},{"key":"e_1_2_6_30_2","first-page":"1262","article-title":"Stimulation of collagen alpha 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury: A link to tissue fibrosis","volume":"19","author":"Bedossa P","year":"1994","journal-title":"Hepatology"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118304"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(91)90598-D"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0098-2997(00)00004-2"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00260-4"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2000.020005387.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2000.02185.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80010-5"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80257-2"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840110322"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2007.04819.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1681.2007.04819.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T15:19:34Z","timestamp":1708269574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2007.04819.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,31]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1111\/j.1440-1681.2007.04819.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2007.04819.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,31]]}}}